Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.57 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.47 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1645224 | 0.88 | MGAM (0.57) | MGAMEGLN1SMN1; SMN2RXRARXRB | |
| SCHEMBL19966737 | 0.86 | HPGDS (0.50) | MGAMEGLN1SMN1; SMN2HDAC6PSMD14 | |
| SCHEMBL27970954 | 0.85 | RXRA (0.62) | MGAMEGLN1RXRARXRBRXRG | |
| SCHEMBL20173757 | 0.84 | ALOX15 (0.50) | SMN1; SMN2OGAHDAC6PSMD14 | |
| SCHEMBL10465639 | 0.81 | MGAM (0.70) | MGAMSMN1; SMN2GABRA1PSMD14 | |
| SCHEMBL10199417 | 0.79 | NPC1 (0.44) | EGLN1SMN1; SMN2 | |
| SCHEMBL7728789 | 0.79 | MGAM (0.62) | MGAMSMN1; SMN2PSMD14 | |
| SCHEMBL61876 | 0.77 | MGAM (0.64) | MGAMGABRA1PSMD14 | |
| SCHEMBL8081677 | 0.76 | KDM4E (0.55) | MLKLSMN1; SMN2RXRARXRBRXRG | |
| SCHEMBL2306751 | 0.76 | MGAM (0.62) | MGAMEGLN1TRPM8PSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, FXR1, SLC10A1 | MGAM 3623/4885EGLN1 3748/4885MLKL 2549/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | MGAM 3623/4885EGLN1 3748/4885MLKL 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.